Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

In a report released on May 27, Jason Butler from Citizens JMP reiterated a Buy rating on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) with a price target of $19.00.

Its fiscal Q1 2025 results, reported on May 15, showed positive operations, with net revenue reaching $20.4 million, driven by product net revenue of $17.2 million. The company beat earnings expectations with a reported EPS of $-0.06, which exceeded the expected $-0.21.

A scientist in a lab coat with a microscope magnifying a sample of a rare disease therapy.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) announced the closing of the sale of its Pediatric Rare Disease Priority Review Voucher (PRV) on April 7 to an undisclosed buyer, supporting the optimistic sentiment for the stock with gross proceeds of $150 million. The proceeds position the company to strengthen its balance sheet and support development programs and commercial launches.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is a commercial-stage company that develops therapies for rare diseases with limited or no treatment options. Its product portfolio focuses on rare neurological and sleep conditions, including Idiopathic Hypersomnia, Urea Cycle Disorders, and Niemann-Pick disease type C.

While we acknowledge the potential of ZVRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZVRA and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best Debt Free IT Penny Stocks To Buy and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.